{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T23:51:18Z","timestamp":1775778678713,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T00:00:00Z","timestamp":1257292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single\u2010agent bendamustine in patients with rituximab\u2010refractory, indolent B\u2010cell lymphoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Eligible patients (N = 100, ages 31\u201084 years) received bendamustine at a dose of 120 mg\/m<jats:sup>2<\/jats:sup> by intravenous infusion on Days 1 and 2 every 21 days for 6 to 8 cycles. Histologies included follicular (62%), small lymphocytic (21%), and marginal zone (16%) lymphomas. Patients had received a median of 2 previous regimens (range, 0\u20106 previous regimens), and 36%were refractory to their most recent chemotherapy regimen. Primary endpoints included overall response rate (ORR) and duration of response (DOR). Secondary endpoints were safety and progression\u2010free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>An ORR of 75% (a 14% complete response rate, a 3% unconfirmed complete response rate, and a 58% partial response rate) was observed. The median DOR was 9.2 months, and median PFS was 9.3 months. Six deaths were considered to be possibly treatment related. Grade 3 or 4 (determined using National Cancer Institute Common Toxicity Criteria [version 3.0.19]. reversible hematologic toxicities included neutropenia (61%), thrombocytopenia (25%), and anemia (10%). The most frequent nonhematologic adverse events (any grade) included nausea (77%), infection (69%), fatigue (64%), diarrhea (42%), vomiting (40%), pyrexia (36%), constipation (31%), and anorexia (24%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Single\u2010agent bendamustine produced a high rate of objective responses with acceptable toxicity in patients with recurrent, rituximab\u2010refractory indolent B\u2010cell lymphoma. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24714","type":"journal-article","created":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T12:15:14Z","timestamp":1257336914000},"page":"106-114","source":"Crossref","is-referenced-by-count":213,"title":["Bendamustine is effective therapy in patients with rituximab\u2010refractory, indolent B\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1002","volume":"116","author":[{"given":"Brad S.","family":"Kahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Ganjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Sue","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,11,4]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"issue":"20","key":"e_1_2_7_5_2","first-page":"424","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP\u2010interferon in follicular lymphoma patients","volume":"18","author":"Foussard C","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_6_2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non\u2010Hodgkin's Lymphomas. Version 3.2008. 04\/10\/08. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nhl.pdfAccessed January 13 2009."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.040"},{"issue":"20","key":"e_1_2_7_9_2","article-title":"Initial therapeutic strategy in follicular lymphoma (FL): an analysis from the National Lymphocare Study (NLCS)","volume":"18","author":"Friedberg JW","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200110000-00003"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0378-6"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701361828"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0023-2"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000223822"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_20_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Published August 9 2006. Available at:http:\/\/ctep.cancer.gov\/proto colDevelopment\/electronic_applications\/docs\/ctcaev3.pdfAccessed January 13 2009."},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1254"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1255"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.368"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4690"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.113"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3035"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_30_2","first-page":"900","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab in the first\u2010line treatment of patients with follicular, indolent and mantle cell lymphomas. Results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL)","volume":"112","author":"Rummel MJ","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:23:13Z","timestamp":1760278993000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24714"}},"subtitle":["Results from a Multicenter Study"],"short-title":[],"issued":{"date-parts":[[2009,11,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/cncr.24714"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24714","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,4]]}}}